Renovacor snags $11 mln Series A

Renovacor Inc, a preclinical-stage biopharmaceutical company focused on developing gene therapy-based treatments for cardiovascular disease, has raised $11 million in Series A financing. Novartis Venture Fund, Broadview Ventures and BioAdvance led the round with participation from New Leaf Venture Partners and Innogest Capital.

North AmericaUSHealthcareBriefs